Envoy Medical COCH Acquired in-process research and development
Acquired in-process research and development at other companies
Other financials
Where this comes from
Reported directly by Envoy Medical in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Envoy Medical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Envoy Medical's acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Envoy Medical's acquired in-process research and development?
- Envoy Medical (COCH) reported acquired in-process research and development of $3.64M in Q1 2026.
- How has Envoy Medical's acquired in-process research and development changed year-over-year?
- Envoy Medical's acquired in-process research and development increased by 32.5% year-over-year, from $2.75M to $3.64M.
- What is the long-term trend for Envoy Medical's acquired in-process research and development?
- Over 2 years (2023 to 2025), Envoy Medical's acquired in-process research and development has grown at a 17.9% compound annual growth rate (CAGR), from $8.99M to $12.49M.
- What does acquired in-process research and development mean?
- Represents the cash consideration paid for research and development projects acquired through business combinations that have not yet reached technological feasibility. This metric highlights capital allocation toward future innovation and pipeline expansion.